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Abstract
Objective: To assess the uptake of postnatal oral glucose tolerance test and to determine the sensitivity of fasting postnatal blood sugar in predicting
2-h impaired glucose tolerance.
Methods: Retrospective study of 1961 women diagnosed with gestational diabetes mellitus. All women were offered oral glucose tolerance test six
weeks post-delivery.
Results: Of 1961 women, 1090 (56%) returned for postpartum oral glucose tolerance test. A fasting plasma glucose of 6.1mmol/l identified only 76
of 167 women with impaired glucose tolerance detected by a 2-h oral glucose tolerance test (sensitivity of 45.5%; 95%CI: 38.1–53.1). We observed a
normal fasting glucose but an impaired 2-h glucose tolerance in 91 out of 968 (9.4%) women. Asian ethnicity, admission on special care baby unit and
antenatal insulin therapy strongly predicted 2-h impaired postnatal blood glucose levels (P50.05).
Conclusion: Although fasting plasma glucose is a convenient method, it lacks sensitivity in identifying women with impaired glucose tolerance
postnatally.
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Introduction
Gestational diabetes (GDM) is deﬁned as glucose intolerance that is
diagnosed for the ﬁrst time in pregnancy1 and aﬀects 4% of pregnant
women.2 With the growing concerns regarding rising body mass index
(BMI) and increased maternal age among women becoming pregnant,
the prevalence of GDM is expected to rise.3,4
Diabetes in pregnancy is associated with risks to the woman and to
the developing fetus;4–6 therefore, early recognition and treatment of
this is likely to have beneﬁts for the maintenance of both short- and
long-term health for mother and the fetus.6,7 Women with a history of
GDM have at least a seven-fold increased risk of developing type 2
diabetes in future compared with women who have normoglycaemic
pregnancies.1,3,8 This is a growing public health concern associated
with a number of serious health complications that reduce both the
life-expectancy and quality of life of those who suﬀer.1,9 There is good
evidence to suggest that intensive lifestyle interventions can reduce type
2 diabetes in high-risk individuals.1,3,4 Thus, a diagnosis of GDM rep-
resents a window of opportunity for implementing these interventions.1
Postpartum glucose testing six weeks after delivery is recommended
for women diagnosed with GDM to identify those at risk of developing
type 2 diabetes, so that timely intervention and preconception care
in subsequent pregnancies can be provided.10–12 Despite this evi-
dence, uptake of postnatal testing for diabetes is poor.10,13
Furthermore, there is inconsistent and limited information on what
constitutes the optimal screening method for identifying women at
risk of diabetes.11,14
This study aimed to (a) assess the uptake of postnatal glucose test-
ing (b) determine the sensitivity of fasting postnatal blood sugar in
predicting 2-h impaired glucose tolerance (IGT) and (c) identify the
strength of association of maternal demographics and pregnancy-
related factors with future risk of diabetes in women with GDM.
Material and methods
We performed a retrospective analysis on all women diagnosed
with GDM at the Jessop Wing Hospital, Sheﬃeld between January
1990 and December 2015. The study was undertaken to determine
the sensitivity of fasting postnatal blood sugar in predicting 2-h IGT
and to assess whether maternal, demographics, antenatal, intrapartum,
postpartum or neonatal variables can identify women with postnatal
IGT. All women with type 2 diabetes were excluded from the study.
Women at risk of developing GDM were selectively screened with
an oral glucose tolerance test (OGTT) at 24–28 weeks of gestation and
were deﬁned as having GDM if they fulﬁlled the World Health
Organization (WHO) criteria for impaired fasting glucose (fasting
plasma glucose 6.1mmol/l) and/or IGT (2-h post challenge plasma
glucose 7.8mmol/l).15 Using these criteria, women diagnosed with
GDM attended a combined Obstetric endocrine clinic for intensive
medical and obstetric management.
All women with GDM were recommended to have a 75 g OGTT six
weeks postpartum to conﬁrm their glucose tolerance status.12 Women
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were advised about the postpartum OGTT and an appointment was
made before hospital discharge. All women and their general practi-
tioners were notiﬁed of the result by letter.
Data for this retrospective review were retrieved from the clinical
database maintained within Jessop Wing Maternity Unit, Sheﬃeld.
Statistical analysis
The diagnostic accuracy of postpartum fasting blood glucose for pre-
dicting postnatal 2-h IGT was evaluated using sensitivity and speciﬁ-
city. The relationship between demographic, antenatal, intrapartum
and postnatal factors for predicting normal fasting blood glucose
and impaired 2-h blood glucose, compared to normal fasting blood
glucose and normal 2-h blood glucose, was assessed using logistic
regression model and results presented as odds ratios (OR) and
95% conﬁdence intervals (CI). Univariable models were ﬁrst applied
to examine the relationship between individual variables and the devel-
opment of the outcome of interest (2-h IGT result). Stepwise multi-
variable logistic regression was used to identify variables that
were statistically signiﬁcant predictors of the outcome of interest.
Diﬀerences between women who did and did not return for postpar-
tum glucose testing were compared using independent samples t-test
for continuous variables and chi-square tests for categorical variables.
All analyses were conducted using SPSS (IBM SPSS Statistics for
Windows, Version 21.0, Armonk, NY).
Results
During the study period, 1961 women were diagnosed with GDM.
The basic maternal, antepartum, intrapartum and postnatal data for
these women and their babies are shown in Table 1.
The mean age of the women was 31.6 years (SD 6.1). Sixty-one
per cent were Caucasians and 28% Asian. Antenatal insulin was com-
menced in 23% of our population. Mean birth weight was 3.3 kg
(SD 0.6) and 81% of the babies required admission on special care
baby unit (SCBU). The main reason for SCBU admission was for the
stabilisation of blood sugar levels.
Of the 1961 women, 1090 (56%) returned for postpartum OGTT.
Participants’ characteristics, stratiﬁed by whether a woman returned
for postpartum glucose screening or not, are shown in Table 2.
Women who returned for postpartum OGTT were predominantly
nulliparous, slightly older, of Asian ethnicity, had higher 2-h blood
sugars at the diagnosis of GDM, required insulin to treat their
GDM, encountered shoulder dystocia at the time of delivery and
their babies required admission on SCBU (P50.05).
Diagnosis and six weeks postnatal OGTT data are summarised
in Table 3.
Although a normal postpartum fasting plasma glucose (56.1mmol/l)
correctly identiﬁed normal 2-h glucose tolerance in 877 of 923 (speci-
ﬁcity of 95.0%; 95%CI: 93.4–96.2), a fasting plasma glucose of
6.1mmol/l identiﬁed only 76 of 167 cases with impaired 2-h glucose
Table 1. Demographic characteristics of women, labour and
birth.
Variable
(n¼ 1961)
Mean (SD)
or count (%)
Age (years) 31.6 (6.1)
BMI 31.7 (7.0)
BMI group
518.5 10 (8.6)
18.5–24.9 259 (13.2)
25–29.9 451 (23.0)
30–34.9 1070 (54.6)
35–40 2 (0.1)
Unknown 169 (8.6)
Ethnic group
Caucasian 1195 (60.9)
Asian 547 (27.9)
African 148 (7.5)
Other 49 (2.5)
Unknown 22 (1.1)
Smoking group
Non-smoker 1754 (89.4)
Smoker 183 (9.3)
Unknown 24 (1.2)
Parity group
Primiparous 628 (32.0)
Multiparous 1327 (67.7)
Unknown 6 (0.3)
Fasting OGTT (antenatal) 5.3 (1.1)
2-h OGTT (antenatal) 8.6 (2.2)
Insulin therapy group
Administered 444 (22.6)
Not administered 1121 (57.1)
Unknown 396 (20.3)
Gestational age at delivery (completed weeks) 37.6 (4.6)
Mode of delivery group
Emergency C-section 420 (21.4)
Elective C-section 331 (16.9)
Normal vaginal delivery 993 (50.6)
Instrumental delivery 205 (10.4)
Unknown 12 (0.6)
Birth weight (kg) 3.3 (0.6)
Birth weight group
53 kg 153 (7.8)
3–4 kg 1568 (80.0)
44 kg 217 (11.1)
Unknown 23 (1.2)
Shoulder dystocia group
Present 21 (1.1)
Absent 1697 (86.5)
Unknown 243 (12.4)
Apgar score at 1min 8.2 (1.8)
Apgar score at 5min 8.9 (1.3)
Birth outcome group
Live births 1936 (98.7)
Still births 19 (1.0)
(continued)
Table 1. Continued
Variable
(n¼ 1961)
Mean (SD)
or count (%)
Unknown 6 (0.3)
SCBU admission
Admitted 261 (13.3)
Not admitted 1585 (80.8)
Unknown 115 (5.9)
OGTT: oral glucose tolerance test; SCBU: special care baby unit; BMI:
body mass index; SD: standard deviation.
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tolerance (sensitivity of 45.5%; 95%CI: 38.1–53.1). Of the 1090 post-
natal OGTTs that were performed, 167 women were diagnosed with
IGT based on raised 2-h plasma glucose level (7.8mmol/l) giving an
incidence of 15.3%, and 122 were diagnosed with IGT based on raised
fasting plasma glucose (6.1mmol/l), giving an incidence of 11.2%.
We observed normal fasting but impaired 2-h blood glucose in 91 out
of 968 women (9.4%).
Univariate analysis was performed to evaluate the association of
maternal characteristics, pregnancy-speciﬁc factors and postpartum
characteristics associated with postnatal IGT in women with GDM.
The results for this analysis are shown in Table 4.
Women from Asian ethnicity were at a 1.5 times higher risk
of impaired 2-h glucose tolerance compared to Caucasians (OR:
1.58; 95% CI: 1.01–2.49). Those who required insulin therapy to
manage GDM demonstrated strong association with IGT compared
to those who did not require insulin treatment (OR: 3.08; 95%
CI: 1.98–4.78). Women whose babies required admission to SCBU
more often exhibited impaired blood glucose compared to those who
did not require SCBU admission (OR: 2.01; 95% CI: 1.17–3.44).
However, when multivariable analysis was conducted, only the use
of insulin remained a signiﬁcant predictor for IGT for women
with GDM.
Table 2. Characteristics of the women stratified by whether they returned for postpartum glucose
testing.
Variables
Postpartum testing (yes) Postpartum testing (no)
Difference
(95% CI) PN
Mean
(SD) or % N
Mean
(SD) or %
Age (y) 611 32.1 (6.4) 741 31.2 (5.8) 1.0
(1.6, 0.3)
0.003
BMI (kg/m2) 1015 31.9 (7.0) 777 31.5 (7.1) 0.3
(1.0, 0.3)
0.300
Parity group
Primiparous 370 34.0 258 29.7 4.3 0.042
Multiparous 717 66.0 610 70.3 (8.4, 0.2)
Ethnicity
Caucasian 652 60.0 543 63.7  50.001
Asian 334 30.7 213 25.0
African 95 8.7 53 6.2
Other 6 0.6 43 5.0
Smoking group
Smoker 82 7.6 101 11.8 4.2
(1.5, 6.9)
0.002
Non-smoker 997 92.4 757 88.2
Fasting OGTT (antenatal) 992 5.3 (1.0) 706 5.3 (1.2) 0.0001
(0.1, 0.1)
0.998
2-h OGTT (antenatal) 993 9.1 (1.7) 708 7.8 (2.5) 1.3
(1.5, 1.1)
50.001
Insulin therapy group
Administered 329 30.2 115 24.1 6.1
(10.9, 1.3)
0.007
Not administered 759 69.8 362 75.9
Gestational age at delivery 1081 37.4 (5.2) 867 37.8 (3.7) 0.4
(0.01, 0.81)
0.057
Shoulder dystocia group
Present 6 0.6 15 2.3 1.7
(0.4, 2.9)
0.002
Absent 1047 (99.4) 650 97.7
Birth weight (kg) 932 3.3 (0.6) 792 3.3 (0.6) 0.02
(0.03, 0.08)
0.455
Apgar scores at 1 min 1084 8.2 (1.8) 484 8.0 (1.9) 0.2
(0.41, 0.02)
0.032
Apgar scores at 5 min 1085 8.9 (1.4) 858 8.9 (1.2) 0.04
(0.08, 0.16)
0.554
SCBU admission
Admitted 169 16.3 92 11.4 4.9
(8.0, 0.2)
0.002
Not admitted 867 83.7 718 88.6
OGTT: oral glucose tolerance test; SCBU: special care baby unit; BMI: body mass index; SD: standard deviation.
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Discussion
Our study revealed two principal ﬁndings. Firstly, postnatal fasting
plasma glucose was not sensitive enough to identify women with
IGT. Secondly, women diagnosed with GDM from an Asian back-
ground, requiring insulin therapy during pregnancy and whose
babies required admission on SCBU were at higher risk of developing
IGT postnatally.
In addition to the above ﬁndings, we observed higher attendance
rates for postpartum screening among older women, those within the
Asian population and those who had high blood sugar levels and
required insulin treatment during pregnancy.
The optimal method of testing to determine whether a woman’s
glucose tolerance has returned to normal remains a subject of some
Table 3. Comparison of fasting blood glucose results and 2-h
blood glucose results for identifying impaired glucose tolerance.
Abnormal 2-h
blood glucose
(7.8mmol/l)
Normal 2-h
blood glucose
(57.8mmol/l) Total
Abnormal fasting blood glucose
(6.1mmol/l)
76 46 122
Normal fasting blood glucose
(56.1mmol/l)
91 877 968
Total 167 923 1090
Table 4. Odds ratios of normal fasting blood glucose but impaired or abnormal 2-h blood glucose compared
to normal fasting blood glucose and normal 2-h blood glucose from univariable logistic regression models.
Variables
Normal postnatal
fasting blood
sugar (N)
Impaired/abnormal
postnatal 2-h glucose
tolerance test (N)
Odds ratio
(95% CI) P
Age (years)a 479 56 0.97 (0.94, 1.02) 0.210
BMIa 824 83 1.00 (0.97, 1.03) 0.996
BMI group 0.226
Normal (18.5–24.9) 116 7 – –
Overweight (25–29.9) 208 24 2.07 (0.87, 4.92) 0.099
Obese (30–34.9) 260 26 1.53 (0.64, 3.65) 0.338
Ethnic group 0.101
Caucasian 540 50 – –
Asian 252 37 1.58 (1.01, 2.49) 0.045
African 78 4 0.55 (0.20, 1.58) 0.268
Other 5 0 – –
Smoking
Non-smoker 805 81 – –
Smoker 66 6 0.90 (0.38, 2.15) 0.818
Parity
Primiparous 301 32 – –
Multiparous 574 58 0.95 (0.60, 1.50) 0.826
Fasting OGTT (antenatal)
Normal (6mmol/l) 693 65 –
Abnormal (46mmol/l) 118 13 1.18 (0.63, 2.20) 0.615
2-h OGTT (antenatal)
Normal (57.8mmol/l) 52 1 – –
Abnormal (7.8mmol/l) 761 77 5.26 (0.72, 38.59) 0.102
Insulin therapy
Not administered 664 46 – –
Administered 211 45 3.08 (1.98, 4.78) 50.001
Gestational age at delivery (completed weeks)a 869 90 0.99 (0.95, 1.02) 0.364
Mode of delivery 0.618
Normal vaginal delivery 433 47 – –
Emergency C-section 204 18 0.81 (0.46, 1.44) 0.475
Elective C-section 143 18 1.16 (0.66, 2.06) 0.614
Instrumental delivery 93 7 0.69 (0.30, 1.58) 0.384
Birth weight (kg)a 739 80 1.30 (0.86, 1.94) 0.212
Birth weight 0.162
53 kg 69 5 0.76 (0.30, 1.94) 0.564
3–4 kg 722 69 – –
(continued)
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debate.7 The American diabetes association,16 the Fifth International
Workshop Conference on Gestational Diabetes17 and the Canadian
Diabetes association18 recommend postnatal OGTT. However, recent
UK guidance published by the National Institute for Clinical
Excellence5 recommends fasting plasma glucose alone. Our data
show that in our population, a signiﬁcant proportion of cases with
IGT would be missed by a postpartum screening policy based on fast-
ing plasma glucose alone. Although fasting plasma glucose has greater
reproducibility compared with an OGTT, it lacks sensitivity in iden-
tifying women with IGT and type 2 diabetes.11,19 Kitzmiller et al.9
reported that among 527 women with GDM, fasting plasma glucose
lacked the sensitivity (34%) to identify IGT and type 2 diabetes in the
postpartum OGTTs performed. Similar observations were made by
Kim and coworkers,11 Hunt and Conway20 and McClean et al.7 Our
own ﬁndings are in agreement with these conclusions and highlight the
potential of missing women at risk of diabetes. Therefore, the greater
convenience of utilising fasting blood glucose needs to be weighed
carefully against its decreased sensitivity, particularly among women
requiring insulin therapy in pregnancy.
The strength of the current study is that it includes a relatively large
number of postpartum women with a history of GDM. The study
cohort was of suﬃcient size to evaluate the relative importance of
multiple clinical risk factors related to the mother, pregnancy and
the neonate for predicting postpartum diabetes. This study also iden-
tiﬁed admission on the neonatal unit as a strong predictor of IGT, not
previously seen in other studies.
The future risk of diabetes appears to be mainly associated with
gestational glycaemic status and not with the mother’s weight or the
baby’s birth weight. Based on multivariable analysis, we found that
women who require insulin treatment during pregnancy are more likely
to develop IGT. This is in agreement with the results of previous
studies.8,13 In contrast to other studies, we did not ﬁnd an association
between: maternal-age, BMI, multiparity, increased levels of either
fasting or 2-h blood glucose during pregnancy, birth weight or fetal
macrosomia and the development of IGT.8,9,13
The signiﬁcant association between Asian ethnicity and IGT is
striking. In the Asian population, fasting blood glucose has much
lower sensitivity than postprandial glucose concentration for the detec-
tion of diabetes,21 implying that it is possible that detection of IGT in
substantial number of these patients would be missed if routine OGTT
was not undertaken for this study cohort. Curtailing the rapidly
increasing prevalence of young-onset diabetes in Asian countries is a
pressing task for healthcare practitioners.21 More eﬀort is needed to
identify these young women as early as possible, because they are one
of the best groups for eﬀective implementation of primary prevention
not only for themselves but also for their oﬀspring and family.
Postpartum glucose testing is an important ﬁrst step in an attempt
to prevent both recurrence of GDM and the development of type 2
diabetes.22 It is clear from many studies that there is a high rate of
non-attendance for postpartum follow-up,23 and the lack of clear com-
munication between secondary and primary care providers to arrange
follow-up has been reported.13,24 Compliance with postpartum glucose
screening and long-term follow-up is low because of the poor percep-
tion by women with GDM of the risk that they have of developing type
2 diabetes.25 The uptake of postnatal testing in our population was
56% which is comparable to that observed in a randomised controlled
trial by Clark et al.26 in which the response rate was 60.5%, when both
patient and doctors received reminders. We observed higher attend-
ance rates for postpartum screening among older women, those within
the Asian population and those who had high blood sugar levels and
required insulin treatment during pregnancy. Although the reasons are
speculative, it is possible that healthcare providers may have stressed
the importance of postpartum screening among these women, given
their high prevalence of diabetes.27
The database from which the material for this report was collated
was designed to ensure that all women were oﬀered a follow-up
appointment and to identify and make contact with those who did
not attend an initial appointment. Poor attendance at postpartum
screening was observed in women of higher parity. In order to further
improve postpartum screening performance, reminders should be
introduced into regular practice.28 If there is lack of response to auto-
mated, live or recorded telephone or e-mail messages to patients and
their doctors, an eﬀort should be made to directly contact the patient,
i.e. via a home visit by a healthcare worker.21 Communication between
hospitals and general practitioners on the mother’s risk of future
diabetes could be improved by providing discharge summaries with
pregnancy-speciﬁc risk factors associated with an increased risk of
IGT, such as insulin administration, admission of baby on the neonatal
unit and OGTT results. An additional beneﬁt of this summary is to
raise the awareness of the individual risk factors as women have been
shown to be more likely to comply with diet and lifestyle changes if
they know their individual risk of future diabetes.13 The implications of
preventing impending diabetes are profound in terms of cost savings
for the individuals and the healthcare system, if signiﬁcant numbers of
these high-risk women can avoid development of diabetes until much
later in life.
Table 4. Continued
Variables
Normal postnatal
fasting blood
sugar (N)
Impaired/abnormal
postnatal 2-h glucose
tolerance test (N)
Odds ratio
(95% CI) P
44 kg 77 13 1.77 (0.93, 3.34) 0.080
Shoulder dystocia
Absent 848 87 – –
Present 3 0 – –
Apgar score at 1 mina 872 91 1.00 (0.88, 1.13) 0.997
Apgar score at 5 mina 873 91 0.96 (0.83, 1.11) 0.583
Delivery outcome
Live birth 873 90 – –
Still birth 2 1 4.85 (0.44, 54.01) 0.199
SCBU admission?
No 730 68 – –
Yes 107 20 2.01 (1.17, 3.44) 0.011
OGTT: oral glucose tolerance test; SCBU: special care baby unit; BMI: body mass index.
aOdds ratio for a one unit increase.
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We acknowledge the inherent limitations in a retrospective analysis,
including the inability to control data quality. Participants for the
study were identiﬁed from medical records; therefore, documentation
and record keeping were inconsistent across time and clinicians.
An additional limitation was the inability to assess the occurrence of
postpartum glucose testing among 36% of women diagnosed with
GDM. Although we examined clinical factors and their relationship
to assess whether a woman returned for postpartum glucose screening,
we were not able to obtain information directly addressing why women
did not turn up for postpartum screening. In order to improve our
ability to screen women postpartum, it would be pertinent to examine
and acquire information on sociocultural status.
We found that women with GDM who require insulin therapy
during pregnancy have substantial risk of IGT, best identiﬁed by a
75-g 2-h OGTT six weeks postpartum. Performance of fasting blood
glucose as opposed to the OGTT will miss a subpopulation of women
at risk. The identiﬁcation of women with IGT is of special importance,
since IGT has a higher sensitivity than impaired fasting blood glucose
for predicting the progression to type 2 diabetes.29 Moreover, since
IGT reﬂects postprandial hyperglycaemia, it may predict a greater car-
diovascular risk, implying that OGTT may be more predictive than
fasting plasma glucose for future cardiovascular disease.30
Diagnosing IGT in women after GDM is important to reduce the
risk of poor glycaemic control at the conception of any subsequent
pregnancy, thereby reducing the risk of fetal abnormalities and other
birth complications.2 Pregnancy is an important point in the life of
woman when she has regular contact with the healthcare system,
thus providing opportunities to inﬂuence the future health of both
mother and child.13 Therefore, every eﬀort should be made to recall
women who had GDM, in order to improve testing rates in this high-
risk population and reduce the number of missed opportunities to
diagnose diabetes.
We recommend that in population where the risk of persistent dia-
betes after pregnancy is high, in particular women who require insulin
treatment during pregnancy, routine postpartum OGTT should be
employed to ensure early detection and appropriate treatment of
abnormal glucose levels to reduce long-term impact of diabetes on
woman’s health. Healthcare providers could use this information to
warn these women and increase their perceived susceptibility and
threat of type 2 diabetes. This information can help in counselling
patients regarding their individual risk while they are still pregnant,
highly motivated and under frequent medical care. Introducing this
concept during pregnancy, especially to those at greatest risk of type
2 diabetes, will improve medical follow-up after delivery and reduce the
burden of diabetes especially in women at risk of young-onset diabetes.
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